Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4 Suppl 14
|
pubmed:dateCreated |
1997-10-22
|
pubmed:abstractText |
A phase II study was performed to investigate the tolerance and efficacy of the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). To date, 24 patients (five with stage IIIB and 19 with stage IV NSCLC) have been treated according to the protocol: gemcitabine 900 mg/m2 was administered on days 1 and 8 as a 30-minute infusion and docetaxel 100 mg/m2 was administered on day 8 as a 1-hour infusion after appropriate premedication. Granulocyte colony-stimulating factor 150 microg/m2 subcutaneously was given on days 9 to 15. Treatment was repeated every 3 weeks. Grade 3/4 granulocytopenia occurred in seven (29%) patients, and one (4%) of these patients developed febrile neutropenia. Grade 3/4 thrombocytopenia and anemia were observed in three (13%) and one (4%) patient, respectively. Grade 2 neurotoxicity and fatigue occurred in one (4%) patient each. Other toxicities were mild. There were no treatment-related deaths. Eight patients experienced a partial response (53.3%; 95% confidence interval, 28.1% to 78.6%), and stable and progressive disease were documented in two (13%) and five (33%) patients, respectively. The median delivered dose was 600 mg/m2/wk and 33 mg/m2/wk for gemcitabine and docetaxel, respectively. These preliminary data suggest that the docetaxel/gemcitabine combination has significant antitumor activity and is well tolerated in chemotherapy-naive patients with NSCLC. The study is ongoing.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0093-7754
|
pubmed:author |
pubmed-author:AndroulakisNN,
pubmed-author:BourosDD,
pubmed-author:DimopoulosM AMA,
pubmed-author:GeorgouliasVV,
pubmed-author:HatzakisKK,
pubmed-author:HatzidakiDD,
pubmed-author:HerasPP,
pubmed-author:KakolyrisSS,
pubmed-author:KalbakisKK,
pubmed-author:KotsakisTT,
pubmed-author:KourousisCC,
pubmed-author:MeramveliotakisNN,
pubmed-author:PapadimitriouCC,
pubmed-author:VardakisNN
|
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S14-22-S14-25
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9335520-Adult,
pubmed-meshheading:9335520-Aged,
pubmed-meshheading:9335520-Antimetabolites, Antineoplastic,
pubmed-meshheading:9335520-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9335520-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9335520-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9335520-Deoxycytidine,
pubmed-meshheading:9335520-Female,
pubmed-meshheading:9335520-Humans,
pubmed-meshheading:9335520-Lung Neoplasms,
pubmed-meshheading:9335520-Male,
pubmed-meshheading:9335520-Middle Aged,
pubmed-meshheading:9335520-Paclitaxel,
pubmed-meshheading:9335520-Taxoids
|
pubmed:year |
1997
|
pubmed:articleTitle |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
|
pubmed:affiliation |
Department of Medical Oncology, School of Medicine, University of Crete, Greece.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|